Find Funding Opportunities

COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements
NINDS Interest in Pain Research | View information, FAQs, resources, and available funding notices and opportunities.

All NINDS-related funding opportunity announcements (FOAs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed.Search the Closed Announcements tab to find expired opportunities. Search the Notices tab to find all Notices.

Learn more about award types and program directors and managers.

NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!

Expiration Date: Tuesday, December 6, 2022FOA Number: RFA-HD-23-036Release Date: Thursday, August 11, 2022Announcement Type: RFA
This Funding Opportunity Announcement (FOA) seeks applications for the Data Innovation and Coordinating Hub/Resource Center (hereafter referred to as the Innovation and Data Hub) for the Maternal Health Research Centers of Excellence initiative. This FOA runs in parallel with companion FOAs that seek applications for Research Centers of Excellence (RFA-HD-23-NNN) and an Implementation Science Hub/Resource Center (RFA-HD-23-NNN). It is expected that the Innovation and Data Hub will provide 1) a coordination infrastructure to foster communication and collaboration for participating Research Centers and the Implementation Science Hub under the Maternal Health Centers of Excellence initiative, 2) a centralized resource to support data collection, facilitate curation, and ensure high-quality data, and 3) provide cutting edge biomedical research informatics and data science expertise to maximize data comparability and facilitate data harmonization. The Innovation and Data Hub itself will not generate new experimental data, but rather will serve as a resource, analytical platform, and portal for available analytical and data tools.
Expiration Date: Tuesday, December 6, 2022FOA Number: RFA-HD-23-037Release Date: Thursday, August 11, 2022Announcement Type: RFA
This Funding Opportunity Announcement (FOA) seeks applications for the Implementation Science Hub/Resource Center for the Maternal Health Research Centers of Excellence initiative. This FOA runs in parallel with companion FOAs that seek applications for Research Centers of Excellence (RFA-HD-23-NNN) and an Innovation and Coordinating Hub/Resource Center (RFA-HD-23-NNN). It is expected that the Implementation Science Hub will serve as a resource to Maternal Health Research Centers of Excellence, with a particular emphasis on assisting in implementing evidence-informed programs, practices and policies to improve maternal health outcomes. The Implementation Science Hub will help bridge the evidence-to-practice gap to support the development and implementation of strategies to inform integrated efforts involving policy and practice changes to improve pregnancy, perinatal, and postpartum care and advance maternal health and maternal health equity. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are strongly encouraged.
Expiration Date: Tuesday, December 6, 2022FOA Number: RFA-HD-23-035Release Date: Thursday, August 11, 2022Announcement Type: RFA
This Funding Opportunity Announcement (FOA) invites applications to participate as a Research Center as part of the Maternal Health Research Centers of Excellence initiative. The purpose of this initiative is to generate innovative approaches to address preventable maternal mortality, decrease severe maternal morbidity, and promote maternal health equity in partnership with communities that are most affected (i.e., Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations). This initiative will use an integrated multi-level approach encompassing social and biobehavioral research strategies to address the multiple contributing factors that lead to adverse maternal health outcomes and health disparities. Significant contributing factors include comorbid conditions (e.g., hypertension, diabetes, mental illness, and substance use disorders) and social determinants of health, which include structural racism and health care system factors. The goal of this initiative is for trans-disciplinary researchers to conduct multi-layered novel research approaches that will have the potential to drastically reduce pregnancy-related and pregnancy-associated maternal deaths and decrease severe maternal morbidity. Studies may be interventional (including effectiveness, comparative effectiveness, optimization, or dissemination and implementation studies), or observational (including health services studies, natural experiments, policy analyses) and may assess both short-term and long-term maternal health outcomes. The Research Centers will be uniquely poised to collaborate on studies and projects with other networks and initiatives such as the NICHD Neonatal Research Network and the NICHD Maternal and Pediatric Precision in Therapeutics (MPRINT) initiative.
Expiration Date: Thursday, October 6, 2022FOA Number: PAR-22-221Release Date: Wednesday, August 10, 2022Announcement Type: PAR
The purpose of this Funding Opportunity Announcement (FOA) is to support studies that expand the use of existing AD/ADRD data resources to drive new discoveries that can lead to better understanding of the relationship between early life social determinants of health (SDOH), adverse childhood experiences (ACEs), AD/ADRD biomarkers, and the development of cognitive impairment and dementia, especially in populations experiencing health disparities.
Expiration Date: Saturday, November 5, 2022FOA Number: RFA-NS-22-062Release Date: Tuesday, August 9, 2022Announcement Type: RFA
The purpose of this NINDS-led Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) initiative is to 1) develop tools, standards, and an Open-source software platform that enables a federated (multiple data repository sites with a single access portal) approach for data sharing and analysis of human digital neuropathological slides and 2) perform software testing to validate and verify that the software and tools developed can be used to perform multisite neuropathological analyses using a federated approach. The federated approach requires a single access point of digital slides from multiple geographically distinct brain banks. The resources developed are expected to also enable cross-site annotation and computational image analysis, including advanced analytic approaches. A critical feature of this FOA includes the broad sharing of neuropathological data to further advance research in this area, including the development of a digital resource for distribution and sharing of assessed neuropathological tissue. Software and tools developed under this initiative are expected to be shared using Open Science principles, and the federated digital library is expected to follow FAIR data sharing principles.
Expiration Date: Thursday, March 7, 2024FOA Number: RFA-NS-22-070Release Date: Tuesday, August 9, 2022Announcement Type: RFA
This funding opportunity announcement (FOA) invites research to develop, characterize, and rigorously validate non-rodent mammalian models of pain, associated outcome measures and/or endpoints that enable translational research for effective pain management. These models are expected to recapitulate molecular, cellular, pathological, behavioral, and/or cognitive aspects of human pain disorders and conditions. Research supported under this FOA is expected to provide well-validated models and measures that facilitate the development of non-opioid analgesic therapeutic interventions with little or no addiction liability.
Expiration Date: Tuesday, November 1, 2022FOA Number: RFA-NS-22-059Release Date: Tuesday, August 2, 2022Announcement Type: RFA
This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer's and related dementias: frontotemporal degeneration (FTD, including Picks disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinsons disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy discovery/development with each stage gated by go/no-go milestones. Applicants may enter the program at the stage appropriate to their research. The R61 phase supports preparatory research stages 1 -3: 1) development of in vitro and/or ex vivo assays that can support therapeutic screening efforts, 2) screening efforts to identify and characterize potential therapeutic agents, and 3) therapeutic optimization, pharmacodynamic and pharmacokinetic studies. The R33 phase supports stage 4, in vivo efficacy studies in an animal model of disease. This FOA supports research to enable competitive follow-on applications that meet the entry criteria for the Blueprint Neurotherapeutics Network, Blueprint Biologics, or other similar later-stage translational programs.
Expiration Date: Tuesday, June 10, 2025FOA Number: RFA-NS-23-003Release Date: Monday, August 1, 2022Announcement Type: RFA
More than 25 million Americans suffer from daily chronic pain, a highly debilitating medical condition that is complex and difficult to manage. In recent decades, there has been an overreliance in the prescription of opioids for chronic pain despite their poor ability to improve function and high addiction liability. This contributed to a significant and alarming epidemic of opioid overdose deaths and addictions. Innovative scientific solutions to develop alternative pain treatment options are thus critically needed. Through targeted research efforts, the NIH HEAL Initiative aims to support the development of safe and effective devices to treat pain with little or no addiction liability. This funding opportunity announcement (FOA) is designed to support interdisciplinary research teams of multiple PD/PIs to investigate the mechanism of action of pain relief by medical devices with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies. Program teams are expected to accomplish goals that require considerable synergy and collaborative interactions. Teams must leverage appropriate multi-disciplinary expertise to develop new principles and methods for experimentation, analysis, and interpretation. Teams are encouraged to consider objectives that will produce major advances in the field of pain relief by medical devices.
Expiration Date: Tuesday, October 25, 2022FOA Number: PAR-23-023Release Date: Monday, July 25, 2022Announcement Type: PAR
The accumulation of misfolded proteins in the brain is a key pathological feature shared by many neurodegenerative diseases that can result in dementia such as Alzheimers Disease, Lewy Body Diseases, Frontotemporal Degeneration, and cerebral amyloid angiopathy. Classical prion diseases such as Creutzfeldt-Jakob Disease are a rare family of neurodegenerative disorders that occur when the cellular prion protein (PrPC) undergoes structural conversion to a pathological form (PrPSc), which is usually triggered by its interaction with an infectious variant of the protein that forces the conformational change. Once this process is initiated, it becomes self-propagating until toxic aggregates accumulate within the CNS, leading to neuronal death. Because misfolded proteins of AD/ADRD have been reported to share some features with pathological prion protein at the structural level, it has thus been proposed that ADRD-relevant proteins such as Alpha, tau, beta-synuclein, and TDP-43 (among others) may exhibit prion-like behaviors that lead to toxic aggregate and tangle formation. The goal of this initiative is to promote studies that increase our understanding of the cellular and molecular mechanisms by which such prion-like conversion events occur and are propagated in AD/ADRD, as well as the downstream mechanisms that trigger neurotoxicity, pathological and circuit changes in the brain.
Expiration Date: Friday, February 16, 2024FOA Number: RFA-MH-22-240Release Date: Friday, July 22, 2022Announcement Type: RFA
The goal of this effort is to support the development and validation of next generation platforms and analytic approaches to precisely quantify behaviors in humans and link them with simultaneously recorded brain activity. Tools used for analyzing behavior should be multi-modal and should be able to be linked to brain activity and thus have the accuracy, specificity, temporal resolution, and flexibility commensurate with tools used to measure and modulate the brain circuits that give rise to those behaviors. This phased award will support novel tool development (i.e., hardware/software) in the R61 phase and synchronization of novel tools for measuring behavior and human brain activity in the R33 phase.